Managing Director at IFC - International Finance Corporation
On the way to achieve vaccine equity, partnerships are key. My thanks to BioNTech SE and kENUP Foundation for having me today in #Marburg to participate in the launch of BioNTech’s Vaccine Equity for Africa Initiative. BioNTech's first modular mRNA manufacturing facility is a critical step towards scalable vaccine production in #Africa. I am very proud of our collaboration with BioNTech SE and kENUP Foundation to fast-track vaccine manufacturing in #Africa, facilitate technology adoption and achieve vaccine equity. It is through partnerships of this kind that we will be able to attract more private sector investments and address vaccine shortages in the region. Let's make it happen!
Love this
Just heard of this few hours ago from Mr Wayne Switzer . Indeed BioNTech SE idea is a good one. The possibility of having vaccine produced in Africa will go along way. And I believe same could be done in producing many other necessary resources
Rajesh R.
2y
Congratulations Makhtar Diop, it's a great news 👏 👍. Have a blessed day 🙏
Erick F.
2y
Thanks for sharing, Makhtar Diop! Congratulations!! Worth also providing support for Africa's capacity to manufacture their own vaccines! For example, #Corbevax with ~90% effectiveness! "This vaccine can be produced at a much larger scale because appropriate manufacturing facilities are already available. Also key to global access is that CORBEVAX can be stored in a regular refrigerator. Therefore, it is possible to produce millions of doses rapidly and distribute them relatively easily. In comparison, producing mRNA vaccines is more expensive and complicated because they are based on newer technologies, rely on highly skilled workers and often require ultralow temperatures for storage and transport. Another major difference is that the CORBEVAX vaccine was developed with global vaccine access in mind. The goal was to make a low-cost, easy-to-produce and -transport vaccine. Key to this, the researchers were not concerned with intellectual property or financial benefit. The vaccine was produced without significant public funding; the US$7 million needed for development was provided by philanthropists." https://theconversation.com/corbevax-a-new-patent-free-covid-19-vaccine-could-be-a-pandemic-game-changer-globally-174672
Rajesh R.
2y
Good luck with it
#bravo #truth
Good luck with
Asaad S.
2y
Well deserved
Thank you sir!
Founder at PJF holdings ltd
2yThanks Makhtar Diop for sharing!